Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® ...

Researchers found that the odds of developing an eye condition that leads to vision loss were about 5 times higher among ...

The UK is one of the heaviest nations in Europe now with 64 per cent of the population overweight or obese, and one in four ...

Mounjaro - the brand name for tirzepatide - has become one of the most talked-about medications in metabolic health, and for good reason. But the conversation around it has gotten tangled up with ...

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

Several leading Indian drugmakers have already secured regulatory approval or recommendations to produce and market generic ...

From Semaglip, Sematop, Semakind to Semastrike, Semaglyn and Semaril, the pipeline of upcoming Ozempic copycats reads like ...

The Tennessee Poison Center is seeing a sharp increase in calls related to tirzepatide and semaglutide exposure over the last ...

AUSTIN, TX / ACCESS Newswire / March 2, 2026 / In modern metabolic medicine, few treatments have reshaped care like GLP-1 receptor agonists. If you are asking what is semaglutide, it is a prescription ...

Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.